66. IgA腎症 Disease details / Clinical trials / Drug dev / DR info

A-623 or AMG 623
   Anthera Pharmaceuticals, Inc
      2014   Phase 2;Phase 3   EUCTR2014-001365-26-CZ   Canada;Czech Republic;Germany;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Malaysia;Philippines;Singapore;Spain;Sweden;Taiwan;Thailand;United Kingdom
   Anthera pharmaceuticals, Inc
      2015   -   EUCTR2014-001365-26-SE   Argentina;Belarus;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Malaysia;Philippines;Poland;Romania;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom
      2015   -   EUCTR2014-001365-26-IT   Argentina;Belarus;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Netherlands;Philippines;Poland;Portugal;Romania;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom
      2015   -   EUCTR2014-001365-26-HU   Argentina;Belarus;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Netherlands;Philippines;Poland;Portugal;Romania;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom
      2015   Phase 2;Phase 3   EUCTR2014-001365-26-ES   Argentina;Belarus;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Netherlands;Philippines;Poland;Portugal;Romania;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom
      2015   Phase 2;Phase 3   EUCTR2014-001365-26-DE   Argentina;Belarus;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Malaysia;Philippines;Poland;Romania;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom
A07ea06
   CROWN OY
      2012   -   EUCTR2012-001923-11-IT   Belgium;Czech Republic;Denmark;Finland;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
Abelmoschus manihot
   Chen Xiangmei
      2014   Phase 4   NCT02231125   China
ACE inhibitor
   Yonsei University
      2016   Phase 4   NCT02981212   Korea, Republic of
ACE inhibitor or angiotensin receptor antagonist
   Peking University First Hospital
      2016   -   NCT03015974   China
ACE/ARB
   Mayo Clinic
      2009   Phase 4   NCT00498368   United States
Acei
   Christian Medical College, Vellore, India
      2024   Phase 4   NCT06676384   India
   Ningxia Medical University General
      2024   Phase 0   ChiCTR2400083794   China
   St. Joseph's Hospital and Medical Center, Phoenix
      2002   Phase 3   NCT00318474   United States
   The First Affiliated Hospital of Zhejiang University
      2009   -   ChiCTR-TRC-09000338   China
   The First Hospital, Peking University
      2006   -   ChiCTR-TRC-06000004   China
   the Second Affiliated Hospital Zhejiang University School of Medicine
      2024   Phase 2   ChiCTR2400079954   China
Acei/ARB and corticosteroids
   Chulalongkorn University
      2012   Phase 4   NCT02571842   Thailand
Acth (acthar) GEL
   Mayo Clinic
      2015   Phase 3   NCT02282930   United States
Acthar 80 unit injection
   Baylor College of Medicine
      2015   Phase 4   NCT02382523   United States
Acthib - polvere E solvente PER soluzione iniettabile 1 flaconcino polvere+1 siringa preriempita solvente 0.5 ML
   NOVARTIS PHARMA AG
      2021   Phase 3   EUCTR2020-001049-38-IT   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Vietnam
ADX-097
   Q32 Bio Inc.
      2024   Phase 2   NCT06419205   United States
Aliskiren
   Chinese University of Hong Kong
      2009   Phase 3   NCT00870493   Hong Kong
   Columbia University
      2009   Phase 4   NCT01129557   United States
   Kagawa University
      2010   Phase 4   NCT01184599   Japan
   The University of Hong Kong
      2009   Phase 4   NCT00922311   China
Allopurinol
   Sun Yat-sen University
      2007   -   NCT00793585   China
ALN-CC5
   Alnylam Pharmaceuticals Inc
      2019   Phase 2   EUCTR2018-002716-27-SE   Canada;France;Malaysia;Philippines;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States
      2019   Phase 2   EUCTR2018-002716-27-GB   Canada;France;Malaysia;Philippines;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States
      2019   Phase 2   EUCTR2018-002716-27-ES   Australia;Canada;France;Germany;Korea, Republic of;Malaysia;Philippines;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States
ALXN1210
   ALEXION PHARMACEUTICALS INCORPORATED
      2021   Phase 2   EUCTR2020-001537-13-IT   Australia;Belgium;Canada;France;Germany;Italy;Korea, Democratic People's Republic of;Netherlands;Poland;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States
   Alexion Pharmaceuticals, Inc.
      2021   Phase 2   EUCTR2020-001537-13-SE   Australia;Belgium;Canada;France;Germany;Italy;Korea, Republic of;Netherlands;Poland;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States
      2021   Phase 2   EUCTR2020-001537-13-FR   Australia;Belgium;Canada;France;Germany;Italy;Korea, Republic of;Netherlands;Poland;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States
      2021   Phase 2   EUCTR2020-001537-13-ES   Australia;Belgium;Canada;France;Germany;Italy;Korea, Republic of;Netherlands;Poland;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States
      2021   Phase 2   EUCTR2020-001537-13-DE   Australia;Belgium;Canada;France;Germany;Italy;Korea, Republic of;Netherlands;Poland;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States
   Dr. Alfons Segarra Medrano
      2022   Phase 4   EUCTR2021-005609-28-ES   Spain
ALXN2050
   Alexion Pharmaceuticals, Inc.
      2022   Phase 2   EUCTR2021-001426-22-DE   Argentina;Australia;Brazil;China;Germany;Israel;Italy;Korea, Republic of;Mexico;Peru;Serbia;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
Ambrisentan
   Peking University First Hospital
      2024   Phase 3   ChiCTR2400080435   China
Angiotensin
   Assistance Publique - Hôpitaux de Paris
      2018   Phase 3   NCT03188887   France
   Christian Medical College, Vellore, India
      2024   Phase 4   NCT06676384   India
Angiotensin blockade
   The University of Hong Kong
      2002   Phase 4   NCT00863252   China
Angiotensin II
   Japanese Study Group of Multiple drug therapy for IgAN
      2004   -   JPRN-C000000341   Japan
ANTI-CD19/bcma CAR NK cells
   Jieyang People's Hospital
      2025   Early Phase 1   NCT06926985   China
APL-2
   Apellis Pharmaceuticals, Inc.
      2018   Phase 2   NCT03453619   United States
ARB
   ARB therapeutic society of IgA nephropathy
      2003   Phase 4   JPRN-C000000380   Japan
   Christian Medical College, Vellore, India
      2024   Phase 4   NCT06676384   India
   Ningxia Medical University General
      2024   Phase 0   ChiCTR2400083794   China
   The First Affiliated Hospital of Zhejiang University
      2009   -   ChiCTR-TRC-09000338   China
   The First Hospital, Peking University
      2006   -   ChiCTR-TRC-06000004   China
   Yonsei University
      2016   Phase 4   NCT02981212   Korea, Republic of
   the Second Affiliated Hospital Zhejiang University School of Medicine
      2024   Phase 2   ChiCTR2400079954   China
ARO-C3
   Arrowhead Pharmaceuticals
      2022   Phase 1/Phase 2   NCT05083364   Australia;Georgia;Germany;Korea, Republic of;New Zealand;Spain;Thailand;United Kingdom
ARO-CFB
   Arrowhead Pharmaceuticals
      2024   Phase 1/Phase 2   NCT06209177   New Zealand
Artesunate
   Dongzhimen Hospital, The First Affiliated Hospital of Beijing University of Chinese Medicine
      2020   Phase 0   ChiCTR2000038104   China
AT-1501
   Eledon Pharmaceuticals
      2022   Phase 2   NCT05125068   Australia;Croatia;Malaysia;New Zealand;Philippines;Poland;Spain;Sri Lanka;Thailand;United Kingdom
   Eledon Pharmaceuticals, Inc
      2022   Phase 2   EUCTR2021-004795-34-PL   Australia;China;Croatia;Malaysia;New Zealand;Philippines;Poland;Spain;Sri Lanka;Thailand
      2022   Phase 2   EUCTR2021-004795-34-ES   Australia;China;Croatia;Malaysia;New Zealand;Philippines;Poland;Spain;Sri Lanka;Thailand
Atacicept
   Israni Rubeen
      2024   Phase 3   JPRN-jRCT2031230629   Argentina;Australia;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hong Kong;India;Ireland;Italy;Japan;Malaysia;Philippines;Poland;Portugal;Singapore;South Korea;Spain;Sri Lanka;Taiwan;Thailand;Turkey;United Kingdom;United States
   Merck KGaA
      2017   Phase 2   EUCTR2016-002262-31-GB   Belgium;Czech Republic;France;Israel;Italy;Japan;Korea, Republic of;Singapore;Spain;Taiwan;United Kingdom;United States
   Vera Therapeutics, Inc.
      2023   Phase 3   NCT04716231   Australia;Belgium;Canada;Czechia;Germany;Greece;India;Korea, Republic of;Malaysia;Poland;Turkey;United Kingdom;United States
      2022   Phase 2   EUCTR2020-004892-41-PL   Australia;Belgium;Canada;Czech Republic;Czechia;Germany;Greece;India;Korea, Republic of;Malaysia;Poland;Turkey;United Kingdom;United States
      2021   Phase 2   EUCTR2020-004892-41-GR   Australia;Belgium;Canada;Czech Republic;Czechia;Germany;Greece;India;Korea, Republic of;Malaysia;Poland;Turkey;United Kingdom;United States
      2021   Phase 2   EUCTR2020-004892-41-DE   Australia;Belgium;Canada;Czech Republic;Czechia;Germany;Greece;India;Korea, Republic of;Malaysia;Poland;Turkey;United Kingdom;United States
      2021   Phase 2   EUCTR2020-004892-41-CZ   Australia;Belgium;Canada;Czech Republic;Czechia;Germany;Greece;India;Korea, Republic of;Malaysia;Poland;Turkey;United Kingdom;United States
      2021   Phase 2   EUCTR2020-004892-41-BE   Australia;Belgium;Canada;Czech Republic;Czechia;Germany;Greece;India;Korea, Republic of;Malaysia;Poland;Turkey;United Kingdom;United States
Atacicept 150 MG
   Merck Biopharma Co., Ltd.
      2017   Phase 2   JPRN-jRCT2080223899   Europe;Japan
   Vera Therapeutics, Inc.
      2024   Phase 2   NCT06674577   United States
Atacicept 25 MG
   EMD Serono Research & Development Institute, Inc.
      2017   Phase 2   NCT02808429   Germany;Japan;United Kingdom;United States
   Merck Biopharma Co., Ltd.
      2017   Phase 2   JPRN-jRCT2080223899   Europe;Japan
Atacicept 75 MG
   EMD Serono Research & Development Institute, Inc.
      2017   Phase 2   NCT02808429   Germany;Japan;United Kingdom;United States
   Merck Biopharma Co., Ltd.
      2017   Phase 2   JPRN-jRCT2080223899   Europe;Japan
ATG-F
   Centre Hospitalier Universitaire de Saint Etienne
      2011   Phase 4   NCT02523768   France
Atrasentan
   CHINOOK THERAPEUTICS, U.S., Inc
      2021   Phase 3   EUCTR2020-003084-26-IT   Argentina;Australia;Brazil;Canada;China;Czech Republic;France;Germany;Hong Kong;India;Ireland;Italy;Japan;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
   Chinook Therapeutics U.S., Inc.
      2022   Phase 3   EUCTR2020-003084-26-PT   Argentina;Australia;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;India;Ireland;Italy;Japan;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2020-003084-26-IE   Argentina;Australia;Brazil;Canada;China;Colombia;Czech Republic;Germany;Hong Kong;India;Ireland;Italy;Japan;Korea, Republic of;New Zealand;Poland;Taiwan;United States
      2021   Phase 3   EUCTR2020-003084-26-PL   Argentina;Australia;Brazil;Canada;China;Colombia;Czech Republic;France;Germany;Hong Kong;India;Ireland;Italy;Japan;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
      2021   Phase 3   EUCTR2020-003084-26-FR   Argentina;Australia;Brazil;Canada;China;Colombia;Czech Republic;France;Germany;Hong Kong;India;Ireland;Italy;Japan;Korea, Republic of;New Zealand;Poland;Portugal;Taiwan;United Kingdom;United States
      2021   Phase 3   EUCTR2020-003084-26-DE   Argentina;Australia;Brazil;Canada;China;Colombia;Czech Republic;France;Germany;Hong Kong;India;Ireland;Italy;Japan;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
      2021   Phase 3   EUCTR2020-003084-26-CZ   Argentina;Australia;Brazil;Canada;China;Colombia;Czech Republic;Czechia;France;Germany;Hong Kong;India;Ireland;Italy;Japan;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
   Chinook Therapeutics, Inc.
      2020   Phase 3   NCT04573478   Argentina;Australia;Brazil;Canada;China;Colombia;Czechia;France;Germany;Hong Kong;India;Ireland;Italy;Japan;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
   Fukui Tomoaki
      2021   Phase 3   JPRN-jRCT2071210028   Argentina;Australia;Brazil;Canada;China;Colombia;Czech Republic;France;Germany;Hong Kong;India;Italy;Japan;New Zealand;Poland;South Korea;Spain;Taiwan;United Kingdom;United States
   Novartis Pharmaceuticals
      2023   Phase 2   NCT06841094   Australia;Brazil;Korea, Republic of;Malaysia;Spain;United States
      2023   Phase 2   NCT05834738   Australia;Brazil;Korea, Republic of;Malaysia;Spain;United States
      2021   Phase 2   NCT04573920   Australia;Italy;Korea, Republic of;Spain;United Kingdom;United States
Avacopan
   Mayo Clinic
      2025   Phase 2   NCT06676579   United States
AVB-S6-500
   Aravive, Inc.
      2019   Phase 2   NCT04042623   United States
Azathioprine
   A. Manzoni Hospital
      1999   Phase 3   NCT01392833   -
   RWTH Aachen
      2008   -   EUCTR2007-000871-41-DE   Germany
Azilsartan
   Chinese Cardiovascular Association-HX Fund
      2023   Phase 4   ChiCTR2300076082   China
Bardoxolone methyl capsules
   Reata, a wholly owned subsidiary of Biogen
      2017   Phase 2   NCT03366337   United States
BCX9930 hydrochloride
   BIOCRYST PHARMACEUTICALS INC.
      2021   Phase 2   EUCTR2020-005855-19-IT   France;Germany;Hungary;Italy;Spain;United Kingdom
   BioCryst Pharmaceuticals Inc
      2022   Phase 2   EUCTR2020-005855-19-HU   France;Germany;Hungary;Italy;Romania;Spain;United Kingdom
      2021   Phase 2   EUCTR2020-005855-19-ES   France;Germany;Hungary;Italy;Spain;United Kingdom
Belimumab
   University of Leicester
      2019   Phase 2   EUCTR2017-004366-10-GB   United Kingdom
Benlysta
   University of Leicester
      2019   Phase 2   EUCTR2017-004366-10-GB   United Kingdom
Bexsero - sospensione iniettabile - USO intramuscolare - siringa preriempita (vetro) - 0.5ML - 1 siringa preriempita CON AGO
   NOVARTIS PHARMA AG
      2022   Phase 3   EUCTR2020-002200-40-IT   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Viet Nam
      2021   Phase 3   EUCTR2020-001049-38-IT   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Vietnam
BIO-kult advanced
   University of Leicester
      2023   -   NCT06767592   United Kingdom
BION-1301
   Chinook Therapeutics, Inc.
      2023   Phase 3   NCT05852938   Argentina;Australia;Belgium;Brazil;Canada;China;Croatia;Czechia;France;Germany;Greece;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Spain;Taiwan;Turkey;United Kingdom;United States
BION-1301 multiple doses
   Novartis Pharmaceuticals
      2019   Phase 1/Phase 2   NCT03945318   Korea, Republic of;United Kingdom;United States
BION-1301 single dose
   Novartis Pharmaceuticals
      2019   Phase 1/Phase 2   NCT03945318   Korea, Republic of;United Kingdom;United States
Blisibimod
   Anthera Pharmaceuticals
      2014   Phase 3   NCT02052219   -
      2013   Phase 2/Phase 3   NCT02062684   Canada;Czech Republic;Czechia;Germany;Hong Kong;Italy;Korea, Republic of;Malaysia;Philippines;Russian Federation;Singapore;Spain;Taiwan;Thailand;United Kingdom
Blisibimod injection
   Anthera Pharmaceuticals, Inc
      2014   Phase 2;Phase 3   EUCTR2014-001365-26-CZ   Canada;Czech Republic;Germany;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Malaysia;Philippines;Singapore;Spain;Sweden;Taiwan;Thailand;United Kingdom
   Anthera pharmaceuticals, Inc
      2015   -   EUCTR2014-001365-26-SE   Argentina;Belarus;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Malaysia;Philippines;Poland;Romania;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom
      2015   -   EUCTR2014-001365-26-IT   Argentina;Belarus;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Netherlands;Philippines;Poland;Portugal;Romania;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom
      2015   -   EUCTR2014-001365-26-HU   Argentina;Belarus;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Netherlands;Philippines;Poland;Portugal;Romania;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom
      2015   Phase 2;Phase 3   EUCTR2014-001365-26-ES   Argentina;Belarus;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Netherlands;Philippines;Poland;Portugal;Romania;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom
      2015   Phase 2;Phase 3   EUCTR2014-001365-26-DE   Argentina;Belarus;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Malaysia;Philippines;Poland;Romania;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom
Blood sample
   Centre Hospitalier Universitaire de Saint Etienne
      2012   -   NCT02526966   France
BNJ441
   Alexion Pharmaceuticals, Inc.
      2021   Phase 2   EUCTR2020-001537-13-SE   Australia;Belgium;Canada;France;Germany;Italy;Korea, Republic of;Netherlands;Poland;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States
      2021   Phase 2   EUCTR2020-001537-13-ES   Australia;Belgium;Canada;France;Germany;Italy;Korea, Republic of;Netherlands;Poland;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States
      2021   Phase 2   EUCTR2020-001537-13-DE   Australia;Belgium;Canada;France;Germany;Italy;Korea, Republic of;Netherlands;Poland;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States
Bortezomib
   Ruijin Hospital
      2022   -   NCT05383547   China
   The Rogosin Institute
      2010   Phase 4   NCT01103778   United States
Budesonide
   CALLIDITAS THERAPEUTICS AB
      2020   Phase 3   EUCTR2020-003308-14-IT   Argentina;Australia;Belarus;Belgium;Canada;Czech Republic;Czechia;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2017-004902-16-IT   Argentina;Australia;Belarus;Belgium;Canada;China;Czech Republic;Czechia;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom
   CROWN OY
      2012   -   EUCTR2012-001923-11-IT   Belgium;Czech Republic;Denmark;Finland;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
   Calliditas Therapeutics AB
      2021   Phase 3   EUCTR2020-003308-14-FI   Argentina;Australia;Belarus;Belgium;Canada;Czech Republic;Czechia;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Turkey;United Kingdom;United States
      2021   Phase 3   EUCTR2020-003308-14-BE   Argentina;Australia;Belarus;Belgium;Canada;Czech Republic;Czechia;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2020-003308-14-SE   Argentina;Australia;Belarus;Belgium;Canada;Czech Republic;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2020-003308-14-PL   Argentina;Australia;Belarus;Belgium;Canada;Czech Republic;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2020-003308-14-GR   Argentina;Australia;Belarus;Belgium;Canada;Czech Republic;Czechia;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2020-003308-14-GB   Argentina;Australia;Belarus;Belgium;Canada;Czech Republic;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2020-003308-14-FR   Argentina;Australia;Belarus;Belgium;Canada;Czech Republic;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2020-003308-14-CZ   Argentina;Australia;Belarus;Belgium;Canada;Czech Republic;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2017-004902-16-SE   Argentina;Australia;Belarus;Belgium;Canada;China;Czech Republic;Czechia;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2017-004902-16-PL   Argentina;Australia;Belarus;Belgium;Canada;China;Czech Republic;Czechia;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2017-004902-16-GB   Argentina;Australia;Belarus;Belgium;Canada;China;Czech Republic;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2017-004902-16-FI   Argentina;Australia;Belarus;Belgium;Canada;China;Czech Republic;Czechia;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2017-004902-16-ES   Argentina;Australia;Belarus;Belgium;Canada;Czech Republic;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2017-004902-16-CZ   Argentina;Australia;Belarus;Belgium;Canada;China;Czech Republic;Czechia;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2017-004902-16-BE   Argentina;Australia;Belarus;Belgium;Canada;China;Czech Republic;Czechia;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
   Pharmalink AB
      2013   -   EUCTR2012-001923-11-ES   Belgium;Czech Republic;Denmark;Finland;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2012   -   EUCTR2012-001923-11-SE   Belgium;Czech Republic;Denmark;Finland;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2012   -   EUCTR2012-001923-11-NL   Belgium;Czech Republic;Denmark;Finland;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2012   -   EUCTR2012-001923-11-GB   Belgium;Czech Republic;Denmark;Finland;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2012   -   EUCTR2012-001923-11-FI   Belgium;Czech Republic;Denmark;Finland;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2012   Phase 2   EUCTR2012-001923-11-DK   Belgium;Czech Republic;Denmark;Finland;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2012   Phase 2   EUCTR2012-001923-11-DE   Belgium;Czech Republic;Denmark;Finland;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2012   Phase 2   EUCTR2012-001923-11-CZ   Belgium;Czech Republic;Denmark;Finland;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2012   Phase 2   EUCTR2012-001923-11-BE   Belgium;Czech Republic;Denmark;Finland;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2005   Phase 2   NCT00767221   Sweden
   The First Affiliated Hospital of Air Force Medical University
      2025   -   ChiCTR2500103064   China
   The First Affiliated Hospital,Sun Yat-sen University
      2025   -   ChiCTR2500097089   China
C09
   RETROPHIN, INC
      2018   Phase 3   EUCTR2017-004605-41-IT   Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
Calcitriol
   Chinese University of Hong Kong
      2006   Phase 4   NCT00319761   Hong Kong
   Osaka University Hospital Department of nephrology
      2007   -   JPRN-UMIN000002474   Japan
   Yonsei University
      2011   -   NCT01237028   Korea, Republic of
CCX168
   Amgen
      2015   Phase 2   NCT02384317   Sweden;United States
   ChemoCentryx, Inc.
      2015   Phase 2   EUCTR2014-003402-33-SE   Belgium;Sweden;United States
      2015   Phase 2   EUCTR2014-003402-33-BE   Belgium;Sweden;United States
Cemdisiran
   Alnylam Pharmaceuticals
      2019   Phase 2   NCT03841448   Canada;France;Malaysia;Philippines;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States
   Alnylam Pharmaceuticals Inc
      2019   Phase 2   EUCTR2018-002716-27-SE   Canada;France;Malaysia;Philippines;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States
      2019   Phase 2   EUCTR2018-002716-27-GB   Canada;France;Malaysia;Philippines;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States
      2019   Phase 2   EUCTR2018-002716-27-ES   Australia;Canada;France;Germany;Korea, Republic of;Malaysia;Philippines;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States
Chinese herb prescription granule plus prednisone
   Shanghai University of Traditional Chinese Medicine
      2010   -   NCT01879514   China
Cilazapril
   The First Hospital, Peking University
      2006   -   ChiCTR-TRC-06000004   China
CM313
   Keymed Biosciences Co.Ltd
      2025   Phase 2   NCT06830395   -
CM338
   Keymed Biosciences Co.Ltd
      2023   Phase 2   NCT05775042   China
Continue their usual therapy
   Sun Yat-sen University
      2007   -   NCT00793585   China
Corticosteroid
   Peking University First Hospital
      2016   -   NCT03015974   China
   Yonsei University
      2016   Phase 4   NCT02981212   Korea, Republic of
Corticotherapy
   Assistance Publique - Hôpitaux de Paris
      2018   Phase 3   NCT03188887   France
Creatinine
   Affiliated Hospital of North Sichuan Medical College
      2024   Phase 0   ChiCTR2500098584   China
Cyclophosphamid
   RWTH Aachen
      2008   -   EUCTR2007-000871-41-DE   Germany
Cyclophosphamide
   Peking University First Hospital
      2016   -   NCT03015974   China
   RWTH Aachen
      2008   -   EUCTR2007-000871-41-DE   Germany
   The First Affiliated Hospital of Air Force Medical University
      2025   -   ChiCTR2500103064   China
   the First Affiliated Hospital of Zhengzhou University
      2024   Phase 4   ChiCTR2400083736   China
Dapagliflozin
   Daping Hospital, Army Medical University
      2023   Phase 4   ChiCTR2300067263   China
   Fondazione Schena - Centro Europeo della Ricerca sulle Malattie Renali
      2022   Phase 3   EUCTR2021-006854-29-IT   Italy
   Shenzhen People's Hospital
      2024   Phase 1   ChiCTR2400088054   China
   Travere Therapeutics, Inc.
      2018   Phase 3   NCT03762850   Australia;Belgium;Croatia;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
Decortin H
   Universitätsklinikum Ulm
      2008   -   EUCTR2007-000443-99-DE   Germany
Dihuang
   Zhejiang Provincal Hospital of Traditional Chinese Medicine
      2021   Phase 0   ChiCTR2100042331   China
Dipyridamole
   Peking University First Hospital
      2016   -   NCT03015974   China
      2013   -   ChiCTR-TRC-13003038   China
   The Japanese Pediatric IgA Nephropathy of Treatment Study Group
      2001   -   JPRN-C000000363   Japan
      1998   -   JPRN-C000000374   Japan
   The Japanese Pediatric IgA Nephropathy of Treatment Study Group
      1998   -   JPRN-C000000375   Japan
Enalapril
   ARB therapeutic society of IgA nephropathy
      2003   Phase 4   JPRN-C000000380   Japan
   National Center for Research Resources (NCRR)
      2000   -   NCT00006137   -
Enalapril valsartan methylprednisone
   Hospital Britanico
      1996   Phase 4   NCT00367562   Argentina
Fecal microbiota transplantation
   Air Force Military Medical University, China
      2017   Phase 2   NCT03633864   China
Felzartamab
   Biogen
      2025   Phase 3   NCT06935357   United States
   HI-Bio, A Biogen Company
      2021   Phase 2   NCT05065970   Australia;Belgium;Bulgaria;Czechia;Georgia;Germany;Japan;Korea, Republic of;Malaysia;Philippines;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States
   Human Immunology Biosciences, Inc
      2021   Phase 2   EUCTR2020-005054-19-DE   Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Georgia;Germany;Japan;Korea, Republic of;Malaysia;Philippines;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States
      2021   Phase 2   EUCTR2020-005054-19-CZ   Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Georgia;Germany;Japan;Korea, Republic of;Malaysia;Philippines;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States
      2021   Phase 2   EUCTR2020-005054-19-BG   Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Georgia;Germany;Japan;Korea, Republic of;Malaysia;Philippines;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States
   MorphoSys AG
      2021   Phase 2   EUCTR2020-005054-19-ES   Australia;Belgium;Bulgaria;Canada;Czechia;Georgia;Germany;Japan;Korea, Republic of;Malaysia;Philippines;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States
      2021   Phase 2   EUCTR2020-005054-19-BE   Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Georgia;Germany;Japan;Korea, Republic of;Malaysia;Philippines;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States
Finerenone
   The Fourth Affiliated Hospital of Zhejiang University School of Medicine
      2022   -   NCT06460987   China
   Zhejiang University
      2024   Phase 3   NCT06580288   -
FOS
   St. Joseph's Hospital and Medical Center, Phoenix
      2002   Phase 3   NCT00318474   United States
Fostamatinib 100 MG
   Rigel Pharmaceuticals
      2014   Phase 2   NCT02112838   Austria;Germany;Hong Kong;Singapore;Switzerland;Taiwan;United Kingdom;United States
Fostamatinib 100 MG tablet
   Rigel Pharmaceuticals Inc
      2014   Phase 2   EUCTR2014-000331-16-GB   Austria;Hong Kong;Singapore;Switzerland;Taiwan;United Kingdom;United States
      2014   Phase 2   EUCTR2014-000331-16-AT   Austria;Hong Kong;Singapore;Switzerland;Taiwan;United Kingdom;United States
Fostamatinib 150 MG
   Rigel Pharmaceuticals
      2014   Phase 2   NCT02112838   Austria;Germany;Hong Kong;Singapore;Switzerland;Taiwan;United Kingdom;United States
Fostamatinib 150 MG tablet
   Rigel Pharmaceuticals Inc
      2014   Phase 2   EUCTR2014-000331-16-GB   Austria;Hong Kong;Singapore;Switzerland;Taiwan;United Kingdom;United States
      2014   Phase 2   EUCTR2014-000331-16-AT   Austria;Hong Kong;Singapore;Switzerland;Taiwan;United Kingdom;United States
Fostamatinib disodium
   Rigel Pharmaceuticals Inc
      2014   Phase 2   EUCTR2014-000331-16-GB   Austria;Hong Kong;Singapore;Switzerland;Taiwan;United Kingdom;United States
      2014   Phase 2   EUCTR2014-000331-16-AT   Austria;Hong Kong;Singapore;Switzerland;Taiwan;United Kingdom;United States
Fostamatinib disodium tablet 100 MG
   Rigel Pharmaceuticals
      2015   Phase 2   NCT02433236   -
Fostamatinib disodium tablet 150 MG
   Rigel Pharmaceuticals
      2015   Phase 2   NCT02433236   -
Gastrus
   Uppsala University Hospital
      2013   -   NCT01781312   Sweden
Glucocorticoid
   Ruijin Hospital
      2024   -   NCT06654596   China
   West China Hospital of Sichuan University
      2025   -   ChiCTR2500096335   China
   the First Affiliated Hospital of Zhengzhou University
      2024   Phase 4   ChiCTR2400083736   China
Glucose
   Assistance Publique - Hôpitaux de Paris
      2018   Phase 3   NCT03188887   France
   Christian Medical College, Vellore, India
      2024   Phase 4   NCT06676384   India
GSK1550188
   University of Leicester
      2019   Phase 2   EUCTR2017-004366-10-GB   United Kingdom
GUT-directed budesonide and SOC
   Christian Medical College, Vellore, India
      2024   Phase 4   NCT06676384   India
Haemophilus influenzae
   NOVARTIS PHARMA AG
      2021   Phase 3   EUCTR2020-001049-38-IT   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Vietnam
Henagliflozin
   Peking University First Hospital
      2024   Phase 3   ChiCTR2400080435   China
Hiberix - polvere E solvente PER soluzione iniettabile PER USO intramuscolare 1 flaconcino DI polvere + 1 siringa preriempita DI solvente DA 0.5 ML
   NOVARTIS PHARMA AG
      2022   Phase 3   EUCTR2020-002200-40-IT   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Viet Nam
      2021   Phase 3   EUCTR2020-001049-38-IT   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Vietnam
High DOSE-VIS649
   Visterra, Inc.
      2020   Phase 2   NCT04287985   Australia;Canada;Hong Kong;India;Japan;Korea, Republic of;Malaysia;Philippines;Singapore;Spain;Sri Lanka;Taiwan;Thailand;United Kingdom;United States
HR19042 capsule
   Jiangsu HengRui Medicine Co., Ltd.
      2023   Phase 1   NCT06922305   China
      2021   Phase 1   NCT04887532   China
HR19042 capsules
   Jiangsu HengRui Medicine Co., Ltd.
      2021   Phase 2   NCT05016323   China
HRS-5965
   Chengdu Suncadia Medicine Co., Ltd.
      2023   Phase 2   NCT06137768   China
HRS-5965 capsules
   Chengdu Suncadia Medicine Co., Ltd.
      2024   Phase 1   NCT06490991   China
HRS-5965 tablets
   Chengdu Suncadia Medicine Co., Ltd.
      2024   Phase 1   NCT06490991   China
HS-10390
   Hansoh BioMedical R&D Company
      2024   Phase 2   NCT06635772   China
HS-10390 tablet
   Hansoh BioMedical R&D Company
      2023   Phase 1   NCT05942625   China
HSK39297 100mgbid
   Haisco Pharmaceutical Group Co., Ltd.
      2024   Phase 2   NCT06670352   China
HSK39297 200mgqd
   Haisco Pharmaceutical Group Co., Ltd.
      2024   Phase 2   NCT06670352   China
HSK39297 50mgbid
   Haisco Pharmaceutical Group Co., Ltd.
      2024   Phase 2   NCT06670352   China
Human soluble recombinant FC-gamma receptor IIB
   Baxalta Innovations GmbH
      2015   -   EUCTR2015-002345-64-CZ   Belgium;Canada;Czech Republic;Denmark;Germany;Hong Kong;Sweden;United Kingdom;United States
Hydroxychloroquine
   Department of Pharmacy, Drum Tower Hospital Affiliated to Nanjing University Medical School
      2021   Phase 1   ChiCTR2100052910   China
   Peking University First Hospital
      2021   Phase 0   ChiCTR2100045306   China
   Shanxi Medical University Second Hospital
      2024   Phase 4   ChiCTR2400093530   China
Hydroxychloroquine and SOC
   Christian Medical College, Vellore, India
      2024   Phase 4   NCT06676384   India
Hydroxychloroquine oral tablet
   Centre Hospitalier Universitaire de Saint Etienne
      2025   Phase 2   NCT06350630   France
Hydroxychloroquine sulfate
   LLiu
      2015   Phase 4   NCT02351752   China
   Peking Union Medical College Hospital
      2016   Phase 4   NCT02765594   China
   Peking University First Hospital
      2016   Phase 2   NCT02942381   China
Immune suppressant
   The Fourth Affiliated Hospital of Zhejiang University School of Medicine
      2022   -   NCT06460987   China
Immunosuppressants
   Guang'anmen Hospital of China Academy of Chinese Medical Sciences
      2019   Phase 2/Phase 3   NCT03418779   China
   The Second Hospital of Shanxi Medical University
      2024   -   ChiCTR2400083991   China
   Tianjin Hospital
      2023   -   ChiCTR2500101762   China
Immunosuppressive treatment
   Yonsei University
      2019   Phase 4   NCT03468972   Korea, Republic of
Inhibace/cozaar
   Peking University
      2006   -   NCT00378443   -
Intensive supportive care
   Yonsei University
      2019   Phase 4   NCT03468972   Korea, Republic of
Intervention FOR incipient patients AT LOW risk OF disease progression
   Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
      2020   -   NCT04438603   China
Intervention FOR patients AT high risk OF disease progression
   Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
      2020   -   NCT04438603   China
Intravenous rituximab
   Chulalongkorn University
      2012   Phase 4   NCT02571842   Thailand
   Mayo Clinic
      2009   Phase 4   NCT00498368   United States
Ionis-FB-LRX
   Ionis Pharmaceuticals, Inc.
      2019   Phase 2   NCT04014335   Australia;Canada;New Zealand;Singapore
Iptacopan
   NOVARTIS PHARMA AG
      2022   Phase 3   EUCTR2020-002200-40-IT   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Viet Nam
   Novartis Pharma AG
      2023   Phase 3   EUCTR2020-002200-40-FR   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Viet Nam
      2021   Phase 3   EUCTR2020-002200-40-CZ   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Viet Nam
      2021   Phase 3   EUCTR2020-001049-38-FR   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Vietnam
      2021   Phase 3   EUCTR2020-001049-38-CZ   Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Viet Nam
      2020   Phase 3   EUCTR2020-001049-38-HU   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Vietnam
      2020   Phase 3   EUCTR2020-001049-38-FI   Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Viet Nam
      2019   Phase 2   EUCTR2017-000891-27-CZ   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Jordan;Korea, Republic of;Lebanon;Malaysia;Netherlands;Norway;Philippines;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2018   Phase 2   EUCTR2017-000891-27-SE   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Jordan;Korea, Republic of;Lebanon;Malaysia;Netherlands;Norway;Philippines;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2018   Phase 2   EUCTR2017-000891-27-NL   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Jordan;Korea, Republic of;Lebanon;Malaysia;Netherlands;Norway;Philippines;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2018   Phase 2   EUCTR2017-000891-27-FI   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Jordan;Korea, Republic of;Lebanon;Malaysia;Netherlands;Norway;Philippines;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2018   Phase 2   EUCTR2017-000891-27-DK   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Jordan;Korea, Republic of;Lebanon;Malaysia;Netherlands;Norway;Philippines;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2018   Phase 2   EUCTR2017-000891-27-DE   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Jordan;Korea, Republic of;Lebanon;Malaysia;Netherlands;Norway;Philippines;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2017   Phase 2   EUCTR2017-000891-27-GB   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Jordan;Korea, Republic of;Lebanon;Malaysia;Netherlands;Norway;Philippines;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
   Novartis Pharmaceuticals
      2025   Phase 2   NCT06797518   -
Iptacopan hydrochloride
   Novartis Pharma AG
      2022   Phase 3   EUCTR2020-002200-40-DK   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States;Viet Nam
      2022   Phase 3   EUCTR2020-001049-38-SK   Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States;Viet Nam
      2022   Phase 3   EUCTR2020-001049-38-SI   Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States;Viet Nam
      2021   Phase 3   EUCTR2020-002200-40-NO   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States;Viet Nam
      2021   Phase 3   EUCTR2020-002200-40-NL   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States;Viet Nam
      2021   Phase 3   EUCTR2020-002200-40-DE   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States;Viet Nam
      2021   Phase 3   EUCTR2020-002200-40-BE   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States;Viet Nam
      2021   Phase 3   EUCTR2020-001049-38-SE   Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States;Viet Nam
      2021   Phase 3   EUCTR2020-001049-38-NO   Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Viet Nam
      2021   Phase 3   EUCTR2020-001049-38-NL   Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States;Viet Nam
      2021   Phase 3   EUCTR2020-001049-38-DK   Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States;Viet Nam
      2021   Phase 3   EUCTR2020-001049-38-BE   Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States;Viet Nam
      2020   Phase 3   EUCTR2020-001049-38-DE   Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States;Viet Nam
Irbesartan
   AZIENDA OSPEDALIERA PROVINCIALE DI LECCO
      2005   -   EUCTR2005-003885-40-IT   Italy
   Hansoh BioMedical R&D Company
      2024   Phase 2   NCT06635772   China
   Sun Yat-sen University
      2007   Phase 3   NCT00657059   China
   Travere Therapeutics, Inc.
      2018   Phase 3   NCT03762850   Australia;Belgium;Croatia;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
   Yueyang Integrated Traditional Chinese and Western Medicine Hospital, Affiliated with Shanghai University of Traditional Chinese Medicine
      2024   Phase 1   ChiCTR2400082620   China
Irbesartan tablets (approved IN THE USA. reference listed drug avapro) NDC # 43547-0374-03
   Retrophin, Inc.
      2018   Phase 3   EUCTR2017-004605-41-GB   Australia;Belgium;Croatia;Czech Republic;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
      2018   Phase 3   EUCTR2017-004605-41-ES   Australia;Belgium;Croatia;Czech Republic;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;Lithuania;Malaysia;New Zealand;Poland;Portugal;Spain;Turkey;United Kingdom;United States
KP104
   Kira Pharmacenticals (US), LLC.
      2025   Phase 2   NCT05517980   -
Leflunomide
   Chinese General Hospital of PLA
      2010   -   ChiCTR-TRC-10000776   China
   The First Affiliated Hospital of Chengdu Medical College
      2018   -   ChiCTR1800019606   China
Leflunomide 20 MG+prednisone 0.5MG/KG/D
   Shenzhen Second People's Hospital
      2019   Phase 4   NCT04020328   China
Lisinopril
   Japanese Study group of Kidney Disease in Children
      2005   -   JPRN-C000000006   Japan
   The Japanese Pediatric IgA Nephropathy of Treatment Study Group
      1998   -   JPRN-C000000373   Japan
LNP023
   Novartis Pharma AG
      2023   Phase 3   EUCTR2020-002200-40-FR   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Viet Nam
      2022   Phase 3   EUCTR2020-002200-40-DK   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States;Viet Nam
      2022   Phase 3   EUCTR2020-001049-38-SK   Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States;Viet Nam
      2022   Phase 3   EUCTR2020-001049-38-SI   Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States;Viet Nam
      2021   Phase 3   EUCTR2020-002200-40-NO   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States;Viet Nam
      2021   Phase 3   EUCTR2020-002200-40-NL   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States;Viet Nam
      2021   Phase 3   EUCTR2020-002200-40-DE   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States;Viet Nam
      2021   Phase 3   EUCTR2020-002200-40-CZ   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Viet Nam
      2021   Phase 3   EUCTR2020-002200-40-BE   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States;Viet Nam
      2021   Phase 3   EUCTR2020-001049-38-SE   Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States;Viet Nam
      2021   Phase 3   EUCTR2020-001049-38-NO   Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Viet Nam
      2021   Phase 3   EUCTR2020-001049-38-NL   Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States;Viet Nam
      2021   Phase 3   EUCTR2020-001049-38-FR   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Vietnam
      2021   Phase 3   EUCTR2020-001049-38-DK   Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States;Viet Nam
      2021   Phase 3   EUCTR2020-001049-38-CZ   Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Viet Nam
      2021   Phase 3   EUCTR2020-001049-38-BE   Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States;Viet Nam
      2020   Phase 3   EUCTR2020-001049-38-HU   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Vietnam
      2020   Phase 3   EUCTR2020-001049-38-FI   Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Viet Nam
      2020   Phase 3   EUCTR2020-001049-38-DE   Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States;Viet Nam
      2019   Phase 2   EUCTR2017-000891-27-IT   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Jordan;Korea, Republic of;Lebanon;Malaysia;Netherlands;Norway;Philippines;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2019   Phase 2   EUCTR2017-000891-27-HU   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Jordan;Korea, Republic of;Lebanon;Malaysia;Netherlands;Norway;Philippines;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2019   Phase 2   EUCTR2017-000891-27-FR   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Jordan;Korea, Republic of;Lebanon;Malaysia;Netherlands;Norway;Philippines;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2019   Phase 2   EUCTR2017-000891-27-CZ   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Jordan;Korea, Republic of;Lebanon;Malaysia;Netherlands;Norway;Philippines;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2018   Phase 2   EUCTR2017-000891-27-SE   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Jordan;Korea, Republic of;Lebanon;Malaysia;Netherlands;Norway;Philippines;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2018   Phase 2   EUCTR2017-000891-27-NL   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Jordan;Korea, Republic of;Lebanon;Malaysia;Netherlands;Norway;Philippines;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2018   Phase 2   EUCTR2017-000891-27-FI   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Jordan;Korea, Republic of;Lebanon;Malaysia;Netherlands;Norway;Philippines;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2018   Phase 2   EUCTR2017-000891-27-DK   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Jordan;Korea, Republic of;Lebanon;Malaysia;Netherlands;Norway;Philippines;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2018   Phase 2   EUCTR2017-000891-27-DE   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Jordan;Korea, Republic of;Lebanon;Malaysia;Netherlands;Norway;Philippines;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2018   Phase 2   EUCTR2017-000891-27-BE   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Jordan;Korea, Republic of;Lebanon;Malaysia;Netherlands;Norway;Philippines;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2017   Phase 2   EUCTR2017-000891-27-GB   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Jordan;Korea, Republic of;Lebanon;Malaysia;Netherlands;Norway;Philippines;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
   Novartis Pharmaceuticals
      2021   Phase 3   NCT04578834   Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Colombia;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Puerto Rico;Russian Federation;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Vietnam
      2021   Phase 3   NCT04557462   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Vietnam
      2018   Phase 2   NCT03373461   Argentina;Australia;Belgium;Brazil;China;Colombia;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Netherlands;Norway;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
LNP023 hydrochlori
   NOVARTIS PHARMA AG
      2022   Phase 3   EUCTR2020-002200-40-IT   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Viet Nam
Losartan
   Chen Xiangmei
      2014   Phase 4   NCT02231125   China
   Fukuoka University Faculty of Medicine
      2009   -   JPRN-UMIN000002887   Japan
   Hu Qianqian
      2018   Phase 0   ChiCTR2200058382   China
   Japanese Study group of Kidney Disease in Children
      2005   -   JPRN-C000000006   Japan
   Jiujiang Hospital of Traditional Chinese Medicine
      2023   Phase 0   ChiCTR2200066983   China
   Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
      2023   Phase 2   ChiCTR2400094993   China
   The First Hospital, Peking University
      2006   -   ChiCTR-TRC-06000004   China
   The Third Xiangya Hospital of Central South University
      2018   Phase 4 study   ChiCTR-IIR-17013487   China
LOW antigen content diet
   Uppsala University Hospital
      2010   -   NCT01203007   Norway;Sweden
LOW DOSE-VIS649
   Visterra, Inc.
      2020   Phase 2   NCT04287985   Australia;Canada;Hong Kong;India;Japan;Korea, Republic of;Malaysia;Philippines;Singapore;Spain;Sri Lanka;Taiwan;Thailand;United Kingdom;United States
MASP-2 antibody, OMS00620646, OMS620646
   Omeros Corporation
      2021   Phase 3   EUCTR2018-000075-33-GR   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Germany;Greece;Hungary;India;Italy;Korea, Republic of;Lithuania;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2018-000075-33-SK   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Germany;Greece;Hungary;India;Italy;Korea, Republic of;Lithuania;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2018-000075-33-SE   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Germany;Greece;Hungary;India;Italy;Korea, Republic of;Lithuania;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2018-000075-33-PL   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Germany;Greece;Hungary;India;Italy;Korea, Republic of;Lithuania;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2018-000075-33-LT   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Germany;Greece;Hungary;India;Italy;Korea, Republic of;Lithuania;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2018-000075-33-BG   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Germany;Greece;Hungary;India;Italy;Korea, Republic of;Lithuania;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2018-000075-33-BE   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Germany;Greece;Hungary;India;Italy;Korea, Republic of;Lithuania;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
Medium DOSE-VIS649
   Visterra, Inc.
      2020   Phase 2   NCT04287985   Australia;Canada;Hong Kong;India;Japan;Korea, Republic of;Malaysia;Philippines;Singapore;Spain;Sri Lanka;Taiwan;Thailand;United Kingdom;United States
Menatetrenone
   Osaka University Hospital Department of nephrology
      2007   -   JPRN-UMIN000002474   Japan
Menveo - polv.E soluz.PER soluz. iniett.-USO intramuscolare-comp. coniug.liofilizz.mena:flac.(vetro) comp. goniug.liqui.mencwy:flac.(vetro)-1 flac+1flac
   NOVARTIS PHARMA AG
      2022   Phase 3   EUCTR2020-002200-40-IT   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Viet Nam
      2021   Phase 3   EUCTR2020-001049-38-IT   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Vietnam
Metformin
   West China Hospital of Sichuan University
      2025   -   ChiCTR2500096335   China
Methylprednisolon
   RWTH Aachen
      2008   -   EUCTR2007-000871-41-DE   Germany
Methylprednisolone
   A. Manzoni Hospital
      1999   Phase 3   NCT01392833   -
   Mayo Clinic
      2025   Phase 2   NCT06676579   United States
   RWTH Aachen
      2008   -   EUCTR2007-000871-41-DE   Germany
   Sixth Affiliated Hospital, Sun Yat-sen University
      2021   Phase 3   NCT04833374   China
   Sun Yat-sen University
      2014   Phase 2   NCT02160132   China
      2007   Phase 3   NCT00657059   China
   The George Institute
      2012   -   NCT01560052   Australia;Canada;China;Hong Kong;India;Malaysia
   Zhongshan Hospital of Fudan University
      2008   -   ChiCTR-TRC-09000607   China
Methylprednisolone mylan GéNérique
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2017   Phase 3   EUCTR2016-004507-31-FR   France
Methylprednisolone pulse
   Peking University First Hospital
      2016   Phase 2/Phase 3   NCT02647255   China
   West Japan Study Group for Therapy of IgA Nephropathy
      2006   -   JPRN-UMIN000000593   Japan
   the First Affiliated Hospital of Zhengzhou University
      2024   Phase 4   ChiCTR2400083736   China
Methylprednisolone succinate
   Fondazione Schena - Centro Europeo della Ricerca sulle Malattie Renali
      2022   Phase 3   EUCTR2021-006854-29-IT   Italy
Metilprednisolone sodio succinato
   Fondazione Schena - Centro Europeo della Ricerca sulle Malattie Renali
      2022   Phase 3   EUCTR2021-006854-29-IT   Italy
Mezagitamab
   Nishizawa Atsushi
      2022   Phase 1   JPRN-jRCT2011220009   Australia;Belgium;China;Hungary;Italy;Japan;Serbia;Singapore;South Korea;Spain;Taiwan;UK;USA
   Takeda
      2025   Phase 3   NCT06963827   -
      2022   Phase 1   NCT05174221   Australia;Belgium;China;Hungary;Italy;Japan;Korea, Republic of;Serbia;Singapore;Spain;Taiwan;United Kingdom;United States
Mizoribine
   Japanese Study Group of Multiple drug therapy for IgAN
      2004   -   JPRN-C000000341   Japan
   Nanjing general hospital of Nanjing military command
      2011   -   ChiCTR-ONC-10001124   China
   Peking University First Hospital
      2013   -   ChiCTR-TRC-13003038   China
   The Japanese Pediatric IgA Nephropathy of Treatment Study Group
      2001   -   JPRN-C000000363   Japan
   The Japanese Pediatric IgA Nephropathy of Treatment Study Group
      1998   -   JPRN-C000000375   Japan
   West Japan Study Group for Therapy of IgA Nephropathy
      2006   -   JPRN-UMIN000000593   Japan
MMF
   Second Xiangya Hospital of Central South University
      2014   Phase 3   NCT02187900   China
   St. Joseph's Hospital and Medical Center, Phoenix
      2002   Phase 3   NCT00318474   United States
   Sun Yat-sen University
      2007   Phase 3   NCT00657059   China
   Zhongshan Hospital of Fudan University
      2008   -   ChiCTR-TRC-09000607   China
MOR03087
   Human Immunology Biosciences, Inc
      2021   Phase 2   EUCTR2020-005054-19-DE   Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Georgia;Germany;Japan;Korea, Republic of;Malaysia;Philippines;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States
      2021   Phase 2   EUCTR2020-005054-19-CZ   Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Georgia;Germany;Japan;Korea, Republic of;Malaysia;Philippines;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States
      2021   Phase 2   EUCTR2020-005054-19-BG   Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Georgia;Germany;Japan;Korea, Republic of;Malaysia;Philippines;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States
   MorphoSys AG
      2021   Phase 2   EUCTR2020-005054-19-ES   Australia;Belgium;Bulgaria;Canada;Czechia;Georgia;Germany;Japan;Korea, Republic of;Malaysia;Philippines;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States
      2021   Phase 2   EUCTR2020-005054-19-BE   Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Georgia;Germany;Japan;Korea, Republic of;Malaysia;Philippines;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States
MOR202
   Human Immunology Biosciences, Inc
      2021   Phase 2   EUCTR2020-005054-19-DE   Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Georgia;Germany;Japan;Korea, Republic of;Malaysia;Philippines;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States
      2021   Phase 2   EUCTR2020-005054-19-CZ   Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Georgia;Germany;Japan;Korea, Republic of;Malaysia;Philippines;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States
      2021   Phase 2   EUCTR2020-005054-19-BG   Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Georgia;Germany;Japan;Korea, Republic of;Malaysia;Philippines;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States
   MorphoSys AG
      2021   Phase 2   EUCTR2020-005054-19-ES   Australia;Belgium;Bulgaria;Canada;Czechia;Georgia;Germany;Japan;Korea, Republic of;Malaysia;Philippines;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States
      2021   Phase 2   EUCTR2020-005054-19-BE   Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Georgia;Germany;Japan;Korea, Republic of;Malaysia;Philippines;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States
MY008211A tablets
   Wuhan Createrna Science and Technology Co., Ltd
      2024   Phase 2   NCT06687174   China
Mycophenolat-natrium
   Universitätsklinikum Ulm
      2008   -   EUCTR2007-000443-99-DE   Germany
Mycophenolate mofetil
   Nanjing University School of Medicine
      2003   -   NCT00301600   China
   Peking University First Hospital
      2016   -   NCT03015974   China
   Second Xiangya Hospital of Central South University
      2014   Phase 3   NCT02187900   China
   St. Joseph's Hospital and Medical Center, Phoenix
      2002   Phase 3   NCT00318474   United States
   Sun Yat-sen University
      2007   Phase 3   NCT00657059   China
   The First Affiliated Hospital of Air Force Medical University
      2025   -   ChiCTR2500103064   China
   The University of Hong Kong
      2002   Phase 4   NCT00863252   China
   Yonsei University
      2016   Phase 4   NCT02981212   Korea, Republic of
   the First Affiliated Hospital of Zhengzhou University
      2024   Phase 4   ChiCTR2400083736   China
Mycophenolate mofetil (MMF) and SOC
   Christian Medical College, Vellore, India
      2024   Phase 4   NCT06676384   India
Mycophenolate mofetil plus lower dose OF prednisone
   Zhi-Hong Liu, M.D.
      2010   -   NCT01269021   China
Mycophenolate sodium
   The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China
      2022   Phase 4   ChiCTR2200060990   China
   UHB NHS Foundation Trust
      2010   Phase 2   EUCTR2009-016003-26-GB   United Kingdom
Mycophenolic acid
   UHB NHS Foundation Trust
      2010   Phase 2   EUCTR2009-016003-26-GB   United Kingdom
Mycophenolic sodium
   UHB NHS Foundation Trust
      2010   Phase 2   EUCTR2009-016003-26-GB   United Kingdom
Myfortic
   Universitätsklinikum Ulm
      2008   -   EUCTR2007-000443-99-DE   Germany
Myfortic 180MG tablets
   UHB NHS Foundation Trust
      2010   Phase 2   EUCTR2009-016003-26-GB   United Kingdom
Myfortic 360MG tablets
   UHB NHS Foundation Trust
      2010   Phase 2   EUCTR2009-016003-26-GB   United Kingdom
Narsoplimab
   Omeros Corporation
      2021   Phase 3   EUCTR2018-000075-33-GR   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Germany;Greece;Hungary;India;Italy;Korea, Republic of;Lithuania;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2018-000075-33-SK   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Germany;Greece;Hungary;India;Italy;Korea, Republic of;Lithuania;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2018-000075-33-SE   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Germany;Greece;Hungary;India;Italy;Korea, Republic of;Lithuania;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2018-000075-33-PL   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Germany;Greece;Hungary;India;Italy;Korea, Republic of;Lithuania;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2018-000075-33-LT   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Germany;Greece;Hungary;India;Italy;Korea, Republic of;Lithuania;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2018-000075-33-BG   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Germany;Greece;Hungary;India;Italy;Korea, Republic of;Lithuania;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2018-000075-33-BE   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Germany;Greece;Hungary;India;Italy;Korea, Republic of;Lithuania;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2016   Phase 2   NCT02682407   Hong Kong;United States
Nefecon
   CALLIDITAS THERAPEUTICS AB
      2020   Phase 3   EUCTR2020-003308-14-IT   Argentina;Australia;Belarus;Belgium;Canada;Czech Republic;Czechia;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2017-004902-16-IT   Argentina;Australia;Belarus;Belgium;Canada;China;Czech Republic;Czechia;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom
   CROWN OY
      2012   -   EUCTR2012-001923-11-IT   Belgium;Czech Republic;Denmark;Finland;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
   Calliditas Therapeutics AB
      2021   Phase 3   EUCTR2020-003308-14-FI   Argentina;Australia;Belarus;Belgium;Canada;Czech Republic;Czechia;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Turkey;United Kingdom;United States
      2021   Phase 3   EUCTR2020-003308-14-BE   Argentina;Australia;Belarus;Belgium;Canada;Czech Republic;Czechia;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2020-003308-14-SE   Argentina;Australia;Belarus;Belgium;Canada;Czech Republic;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2020-003308-14-PL   Argentina;Australia;Belarus;Belgium;Canada;Czech Republic;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2020-003308-14-GR   Argentina;Australia;Belarus;Belgium;Canada;Czech Republic;Czechia;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2020-003308-14-GB   Argentina;Australia;Belarus;Belgium;Canada;Czech Republic;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2020-003308-14-FR   Argentina;Australia;Belarus;Belgium;Canada;Czech Republic;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2020-003308-14-CZ   Argentina;Australia;Belarus;Belgium;Canada;Czech Republic;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2018   Phase 3   NCT03643965   Argentina;Australia;Belarus;Belgium;Canada;Czechia;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2017-004902-16-SE   Argentina;Australia;Belarus;Belgium;Canada;China;Czech Republic;Czechia;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2017-004902-16-PL   Argentina;Australia;Belarus;Belgium;Canada;China;Czech Republic;Czechia;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2017-004902-16-GB   Argentina;Australia;Belarus;Belgium;Canada;China;Czech Republic;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2017-004902-16-FI   Argentina;Australia;Belarus;Belgium;Canada;China;Czech Republic;Czechia;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2017-004902-16-ES   Argentina;Australia;Belarus;Belgium;Canada;Czech Republic;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2017-004902-16-CZ   Argentina;Australia;Belarus;Belgium;Canada;China;Czech Republic;Czechia;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2017-004902-16-BE   Argentina;Australia;Belarus;Belgium;Canada;China;Czech Republic;Czechia;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
   Everest Medicines (Singapore) Pte. Ltd.
      2022   Phase 3   NCT05534919   China
   Pharmalink AB
      2013   -   EUCTR2012-001923-11-ES   Belgium;Czech Republic;Denmark;Finland;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2012   Phase 2   NCT01738035   Belgium;Czech Republic;Denmark;Finland;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2012   -   EUCTR2012-001923-11-SE   Belgium;Czech Republic;Denmark;Finland;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2012   -   EUCTR2012-001923-11-NL   Belgium;Czech Republic;Denmark;Finland;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2012   -   EUCTR2012-001923-11-GB   Belgium;Czech Republic;Denmark;Finland;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2012   -   EUCTR2012-001923-11-FI   Belgium;Czech Republic;Denmark;Finland;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2012   Phase 2   EUCTR2012-001923-11-DK   Belgium;Czech Republic;Denmark;Finland;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2012   Phase 2   EUCTR2012-001923-11-DE   Belgium;Czech Republic;Denmark;Finland;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2012   Phase 2   EUCTR2012-001923-11-CZ   Belgium;Czech Republic;Denmark;Finland;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2012   Phase 2   EUCTR2012-001923-11-BE   Belgium;Czech Republic;Denmark;Finland;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
Nefecon 16MG daily
   Calliditas Therapeutics AB
      2020   Phase 3   NCT04541043   Argentina;Australia;Belarus;Belgium;Canada;Czechia;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Turkey;United Kingdom;United States
NM8074
   NovelMed Therapeutics
      2025   Phase 2   NCT06454110   -
NON-steroidal mineralocorticoid receptor antagonist and SOC
   Christian Medical College, Vellore, India
      2024   Phase 4   NCT06676384   India
NTQ5082 capsules 100 MG
   Nanjing Chia-tai Tianqing Pharmaceutical
      2025   Phase 2   NCT06982040   -
NTQ5082 capsules 200 MG
   Nanjing Chia-tai Tianqing Pharmaceutical
      2025   Phase 2   NCT06982040   -
NTQ5082 capsules 300 MG
   Nanjing Chia-tai Tianqing Pharmaceutical
      2025   Phase 2   NCT06982040   -
Omega-3 fatty acid ethylester90
   Kuhnil Pharmaceutical Co., Ltd.
      2007   Phase 3   NCT00549692   Korea, Republic of
Omega-3 fatty acid fish OIL supplement
   Mayo Clinic
      2009   Phase 4   NCT00498368   United States
OMS721
   OMEROS CORPORATION
      2019   Phase 3   EUCTR2018-000075-33-IT   Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Germany;Hungary;Italy;Korea, Democratic People's Republic of;Lithuania;Malaysia;Philippines;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;United Kingdom;United States
   Omeros Corporation
      2021   Phase 3   EUCTR2018-000075-33-GR   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Germany;Greece;Hungary;India;Italy;Korea, Republic of;Lithuania;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-000075-33-GB   Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Lithuania;Malaysia;Philippines;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;United Kingdom;United States
      2019   Phase 3   EUCTR2018-000075-33-DE   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Germany;Greece;Hungary;India;Italy;Korea, Republic of;Lithuania;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2018   Phase 3   NCT03608033   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czechia;Germany;Greece;Hungary;India;Italy;Korea, Republic of;Lithuania;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2018-000075-33-SK   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Germany;Greece;Hungary;India;Italy;Korea, Republic of;Lithuania;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2018-000075-33-SE   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Germany;Greece;Hungary;India;Italy;Korea, Republic of;Lithuania;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2018-000075-33-PL   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Germany;Greece;Hungary;India;Italy;Korea, Republic of;Lithuania;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2018-000075-33-LT   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Germany;Greece;Hungary;India;Italy;Korea, Republic of;Lithuania;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2018-000075-33-HU   Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Germany;Greece;Hungary;Italy;Lithuania;Poland;Slovakia;Spain;Sweden;United Kingdom;United States
      2018   Phase 3   EUCTR2018-000075-33-ES   Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Lithuania;Poland;Slovakia;Spain;Sweden;United Kingdom;United States
      2018   Phase 3   EUCTR2018-000075-33-CZ   Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Germany;Greece;Hungary;Italy;Korea, Republic of;Lithuania;Malaysia;Philippines;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;United Kingdom;United States
      2018   Phase 3   EUCTR2018-000075-33-BG   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Germany;Greece;Hungary;India;Italy;Korea, Republic of;Lithuania;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2018-000075-33-BE   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Germany;Greece;Hungary;India;Italy;Korea, Republic of;Lithuania;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2018-000075-33-AT   Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Hungary;Korea, Republic of;Lithuania;Malaysia;Philippines;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;United States
      2016   Phase 2   NCT02682407   Hong Kong;United States
OPL-CCL2-LPM
   Osprey Pharmaceuticals USA, Inc.
      2009   Phase 1   NCT00856674   Canada
Optimized supportive care
   Guang'anmen Hospital of China Academy of Chinese Medical Sciences
      2019   Phase 2/Phase 3   NCT03418779   China
Oral prednisolone and SOC
   Christian Medical College, Vellore, India
      2024   Phase 4   NCT06676384   India
OVER-encapsulated 150 MG irbesartan tablets
   Retrophin, Inc.
      2018   Phase 3   EUCTR2017-004605-41-ES   Australia;Belgium;Croatia;Czech Republic;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;Lithuania;Malaysia;New Zealand;Poland;Portugal;Spain;Turkey;United Kingdom;United States
OVER-encapsulated irbesartan tablets
   RETROPHIN, INC
      2018   Phase 3   EUCTR2017-004605-41-IT   Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
   Travere Therapeutics Inc.
      2019   Phase 3   EUCTR2017-004605-41-PT   Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
      2019   Phase 3   EUCTR2017-004605-41-PL   Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
      2019   Phase 3   EUCTR2017-004605-41-DE   Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
      2018   Phase 3   EUCTR2017-004605-41-LT   Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
      2018   Phase 3   EUCTR2017-004605-41-HR   Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
      2018   Phase 3   EUCTR2017-004605-41-EE   Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
      2018   Phase 3   EUCTR2017-004605-41-CZ   Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
      2018   Phase 3   EUCTR2017-004605-41-BE   Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
Paricalcitol
   Chinese University of Hong Kong
      2008   Phase 3   NCT00599963   China;Hong Kong
Pneumovax – soluzione iniettabile IN siringa preriempita DA 0,5 ML
   NOVARTIS PHARMA AG
      2022   Phase 3   EUCTR2020-002200-40-IT   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Viet Nam
      2021   Phase 3   EUCTR2020-001049-38-IT   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Vietnam
Potassium
   Hu Qianqian
      2018   Phase 0   ChiCTR2200058382   China
   Jiujiang Hospital of Traditional Chinese Medicine
      2023   Phase 0   ChiCTR2200066983   China
   Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
      2023   Phase 2   ChiCTR2400094993   China
   The Third Xiangya Hospital of Central South University
      2018   Phase 4 study   ChiCTR-IIR-17013487   China
   Yueyang Integrated Traditional Chinese and Western Medicine Hospital, Affiliated with Shanghai University of Traditional Chinese Medicine
      2024   Phase 1   ChiCTR2400082620   China
Prednisolon
   RWTH Aachen
      2008   -   EUCTR2007-000871-41-DE   Germany
   Universitätsklinikum Ulm
      2008   -   EUCTR2007-000443-99-DE   Germany
Prednisolone
   Japanese Study Group of Multiple drug therapy for IgAN
      2004   -   JPRN-C000000341   Japan
   Juntendo University
      2018   -   JPRN-UMIN000032031   Japan
   Mayo Clinic
      2025   Phase 2   NCT06676579   United States
   Nephrology Department, Hangzhou Hospital of Traditional Chinese Medicine, Zhejiang Province
      2019   Phase 0   ChiCTR1900026883   China
   RWTH Aachen
      2008   -   EUCTR2007-000871-41-DE   Germany
   Sun Yat-sen University
      2016   Phase 2/Phase 3   NCT02662283   China
   The Japanese Pediatric IgA Nephropathy of Treatment Study Group
      2001   -   JPRN-C000000363   Japan
      1998   -   JPRN-C000000374   Japan
   The Japanese Pediatric IgA Nephropathy of Treatment Study Group
      1998   -   JPRN-C000000375   Japan
   UHB NHS Foundation Trust
      2010   Phase 2   EUCTR2009-016003-26-GB   United Kingdom
   West Japan Study Group for Therapy of IgA Nephropathy
      2006   -   JPRN-UMIN000000593   Japan
Prednisolone plus cyclophosphamide
   Air Force Military Medical University, China
      2024   Phase 3   NCT05510323   China
Prednisone
   A. Manzoni Hospital
      1999   Phase 3   NCT01392833   -
   Department of Nephrology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine
      2010   -   ChiCTR-TRC-13003702   China
   Fondazione Schena - Centro Europeo della Ricerca sulle Malattie Renali
      2022   Phase 3   EUCTR2021-006854-29-IT   Italy
   Mayo Clinic
      2025   Phase 2   NCT06676579   United States
   Peking University
      2006   -   NCT00378443   -
   Shanghai University of Traditional Chinese Medicine
      2016   -   NCT02712697   China
   Sun Yat-sen University
      2007   Phase 3   NCT00657059   China
   The First Affiliated Hospital of Xi'an Jiaotong University Medical College
      2010   -   ChiCTR-TRC-10000824   China
   The First Affiliated Hospital of Zhejiang University
      2009   -   ChiCTR-TRC-09000338   China
   The First Hospital, Peking University
      2006   -   ChiCTR-TRC-06000004   China
   Xijing hospital
      2023   Phase 4   ChiCTR2300076949   China
   Yancheng Third People's Hospital
      2011   -   ChiCTR-OPN-16010028   -
   the First Affiliated Hospital of Zhengzhou University
      2024   Phase 4   ChiCTR2400083736   China
Prednisone 5 MG
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2017   Phase 3   EUCTR2016-004507-31-FR   France
Prednisone alone
   Guangdong General Hospital
      2016   Phase 4   NCT03218852   China
      2012   Phase 4   NCT01758120   China
Prednisone and cyclophosphamide
   Guangdong General Hospital
      2016   Phase 4   NCT03218852   China
Prednisone arrow 20MG
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2017   Phase 3   EUCTR2016-004507-31-FR   France
Prednisone arrow 5 MG
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2017   Phase 3   EUCTR2016-004507-31-FR   France
Prednisone IN full dose
   Zhi-Hong Liu, M.D.
      2010   -   NCT01269021   China
Prednisone or prednisolone
   Nanjing University School of Medicine
      2011   -   NCT01451710   China
Prednisone plus cyclophosphamide
   Guangdong General Hospital
      2012   Phase 4   NCT01758120   China
Probiotics combined with enteric-coated budesonide capsule
   Gang Xu
      2024   Phase 4   NCT06528015   China
Probucol
   Guangdong General Hospital
      2007   Phase 4   NCT00426348   China
Proline
   the Second Affiliated Hospital Zhejiang University School of Medicine
      2024   Phase 2   ChiCTR2400079954   China
Protectis
   Uppsala University Hospital
      2013   -   NCT01781312   Sweden
R935788
   Rigel Pharmaceuticals Inc
      2014   Phase 2   EUCTR2014-000331-16-GB   Austria;Hong Kong;Singapore;Switzerland;Taiwan;United Kingdom;United States
      2014   Phase 2   EUCTR2014-000331-16-AT   Austria;Hong Kong;Singapore;Switzerland;Taiwan;United Kingdom;United States
Ramipril
   AZIENDA OSPEDALIERA PROVINCIALE DI LECCO
      2005   -   EUCTR2005-003885-40-IT   Italy
   Chinese University of Hong Kong
      2002   Phase 3   NCT01225445   Hong Kong
   The Chinese University of Hong Kong
      2004   -   ChiCTR-TRC-09000630   China
Rapamune
   NEPHROLOGY DEPARTMENT (HOSPITAL UNIVERSITARY OF BELLVITGE)
      2005   -   EUCTR2005-002610-37-ES   Spain
RAS
   Assistance Publique - Hôpitaux de Paris
      2018   Phase 3   NCT03188887   France
   Tianjin Hospital
      2023   -   ChiCTR2500101762   China
RAS 2410
   Nan Chen,MD
      2020   Phase 4   NCT04525729   China
RAS inhibitor
   Ruijin Hospital
      2023   -   NCT06589752   China
   The Fourth Affiliated Hospital of Zhejiang University School of Medicine
      2022   -   NCT06460987   China
Ravulizumab
   ALEXION PHARMACEUTICALS INCORPORATED
      2021   Phase 2   EUCTR2020-001537-13-IT   Australia;Belgium;Canada;France;Germany;Italy;Korea, Democratic People's Republic of;Netherlands;Poland;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States
   Alexion Pharmaceuticals, Inc.
      2021   Phase 2   EUCTR2020-001537-13-SE   Australia;Belgium;Canada;France;Germany;Italy;Korea, Republic of;Netherlands;Poland;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States
      2021   Phase 2   EUCTR2020-001537-13-FR   Australia;Belgium;Canada;France;Germany;Italy;Korea, Republic of;Netherlands;Poland;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States
      2021   Phase 2   EUCTR2020-001537-13-ES   Australia;Belgium;Canada;France;Germany;Italy;Korea, Republic of;Netherlands;Poland;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States
      2021   Phase 2   EUCTR2020-001537-13-DE   Australia;Belgium;Canada;France;Germany;Italy;Korea, Republic of;Netherlands;Poland;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States
   Dr. Alfons Segarra Medrano
      2022   Phase 4   EUCTR2021-005609-28-ES   Spain
RC18 160MG
   RemeGen Co., Ltd.
      2020   Phase 2   NCT04291781   China
RC18 240MG
   RemeGen Co., Ltd.
      2020   Phase 2   NCT04291781   China
RE-021
   RETROPHIN, INC
      2018   Phase 3   EUCTR2017-004605-41-IT   Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
   Retrophin, Inc.
      2018   Phase 3   EUCTR2017-004605-41-GB   Australia;Belgium;Croatia;Czech Republic;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
      2018   Phase 3   EUCTR2017-004605-41-ES   Australia;Belgium;Croatia;Czech Republic;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;Lithuania;Malaysia;New Zealand;Poland;Portugal;Spain;Turkey;United Kingdom;United States
   TRAVERE THERAPEUTICS, INC
      2022   Phase 2   EUCTR2021-000621-27-IT   France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
   Travere Therapeutics Inc.
      2019   Phase 3   EUCTR2017-004605-41-PT   Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
      2019   Phase 3   EUCTR2017-004605-41-PL   Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
      2019   Phase 3   EUCTR2017-004605-41-DE   Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
      2018   Phase 3   EUCTR2017-004605-41-LT   Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
      2018   Phase 3   EUCTR2017-004605-41-HR   Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
      2018   Phase 3   EUCTR2017-004605-41-EE   Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
      2018   Phase 3   EUCTR2017-004605-41-CZ   Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
      2018   Phase 3   EUCTR2017-004605-41-BE   Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
   Travere Therapeutics, Inc.
      2022   Phase 2   EUCTR2021-000621-27-SE   France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
      2022   Phase 2   EUCTR2021-000621-27-NL   France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
      2022   Phase 2   EUCTR2021-000621-27-FR   France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
      2021   Phase 2   EUCTR2021-000621-27-ES   France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
      -   Phase 2   EUCTR2021-000621-27-PL   France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
      -   Phase 2   EUCTR2021-000621-27-DE   France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
   University of Leicester
      2019   Phase 2   EUCTR2018-002012-27-GB   United Kingdom
REH-acteoside
   Sun Yat-sen University
      2016   Phase 2/Phase 3   NCT02662283   China
Risedronate
   Osaka University Hospital Department of nephrology
      2007   -   JPRN-UMIN000002474   Japan
Rituximab
   Nan Chen,MD
      2020   Phase 4   NCT04525729   China
   Ruijin Hospital, Shanghai Jiaotong University School of Medicine
      2020   Phase 4   ChiCTR2000036468   China
SC0062 high dose
   Biocity Biopharmaceutics Co., Ltd.
      2023   Phase 2   NCT05687890   China
SC0062 LOW dose
   Biocity Biopharmaceutics Co., Ltd.
      2023   Phase 2   NCT05687890   China
SC0062 medium dose
   Biocity Biopharmaceutics Co., Ltd.
      2023   Phase 2   NCT05687890   China
SC0062 strength 10MG
   Biocity Biopharmaceutics Co., Ltd.
      2025   Phase 3   NCT06819826   China
SCTC21C
   Sinocelltech Ltd.
      2025   Phase 1/Phase 2   NCT06774664   China
SGB-9768
   Suzhou Sanegene Bio Inc.
      2025   Phase 2   NCT06786338   China
SHR-2010 injection
   Guangdong Hengrui Pharmaceutical Co., Ltd
      2023   Phase 2   NCT05847920   China
      2022   Phase 1   NCT05398510   China
Sibeprenlimab
   Otsuka Pharmaceutical Development & Commercialization, Inc.
      2024   Phase 2   NCT06740526   Canada;United States
Simulect
   Centre Hospitalier Universitaire de Saint Etienne
      2011   Phase 4   NCT02523768   France
Simvastatin
   Fukuoka University Faculty of Medicine
      2009   -   JPRN-UMIN000002887   Japan
Sirolimus
   NEPHROLOGY DEPARTMENT (HOSPITAL UNIVERSITARY OF BELLVITGE)
      2005   -   EUCTR2005-002610-37-ES   Spain
   Peking Union Medical College Hospital
      2022   Phase 4   ChiCTR2200066031   China
Sirolimus (study drug)+ACE inhibitor + statin
   Josep m Cruzado
      2006   Phase 2   NCT00396721   Spain
SM101
   Baxalta Innovations GmbH
      2015   -   EUCTR2015-002345-64-CZ   Belgium;Canada;Czech Republic;Denmark;Germany;Hong Kong;Sweden;United Kingdom;United States
   Baxalta now part of Shire
      2015   Phase 2   NCT02605525   -
Solu medrol - 1000 MG/16 ML polvere E solvente PER soluzione iniettabile 1 flacone DI polvere DA 1000 MG+ 1 flacone solvente DA 16 ML
   Fondazione Schena - Centro Europeo della Ricerca sulle Malattie Renali
      2022   Phase 3   EUCTR2021-006854-29-IT   Italy
Sparsentan
   Retrophin, Inc.
      2018   Phase 3   EUCTR2017-004605-41-ES   Australia;Belgium;Croatia;Czech Republic;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;Lithuania;Malaysia;New Zealand;Poland;Portugal;Spain;Turkey;United Kingdom;United States
   TRAVERE THERAPEUTICS, INC
      2022   Phase 2   EUCTR2021-000621-27-IT   France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
   Travere Therapeutics, Inc.
      2022   Phase 2   EUCTR2021-000621-27-SE   France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
      2022   Phase 2   EUCTR2021-000621-27-NL   France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
      2022   Phase 2   EUCTR2021-000621-27-FR   France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
      2021   Phase 2   EUCTR2021-000621-27-ES   France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
      2018   Phase 3   NCT03762850   Australia;Belgium;Croatia;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
      -   Phase 2   EUCTR2021-000621-27-PL   France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
      -   Phase 2   EUCTR2021-000621-27-DE   France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
   University of Leicester
      2019   Phase 2   EUCTR2018-002012-27-GB   United Kingdom
Sparsentan compresse
   RETROPHIN, INC
      2018   Phase 3   EUCTR2017-004605-41-IT   Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
Sparsentan tablets/OVER-encapsulated sparsentan tablets
   Travere Therapeutics Inc.
      2019   Phase 3   EUCTR2017-004605-41-PT   Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
      2018   Phase 3   EUCTR2017-004605-41-LT   Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
      2018   Phase 3   EUCTR2017-004605-41-HR   Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
      2018   Phase 3   EUCTR2017-004605-41-EE   Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
      2018   Phase 3   EUCTR2017-004605-41-CZ   Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
      2018   Phase 3   EUCTR2017-004605-41-BE   Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
Sparsentan tablets/OVER-encapsulated spasenten tablets
   Travere Therapeutics Inc.
      2019   Phase 3   EUCTR2017-004605-41-PL   Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
Sparsentan tablets/overencapsulated sparsentan tablets
   Retrophin, Inc.
      2018   Phase 3   EUCTR2017-004605-41-GB   Australia;Belgium;Croatia;Czech Republic;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
   Travere Therapeutics Inc.
      2019   Phase 3   EUCTR2017-004605-41-DE   Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
Steroids plus azathioprine
   A. Manzoni Hospital
      1998   Phase 4   NCT00755859   Italy;Switzerland
Supportive and immunosuppressive therapy
   RWTH Aachen University
      2008   Phase 3   NCT00554502   Germany
Supportive therapy
   RWTH Aachen
      2008   -   EUCTR2007-000871-41-DE   Germany
   Tianjin Hospital
      2023   -   ChiCTR2500101762   China
Supportive therapy with: ACE-inhibitor / ARB / statin
   RWTH Aachen University
      2008   Phase 3   NCT00554502   Germany
Tacrolimus
   Astellas Pharma Inc
      2010   Phase 2   NCT01224028   Korea, Republic of
   Kidney Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University
      2015   -   ChiCTR-IPR-15006760   China
Tailored diet
   Uppsala University Hospital
      2010   -   NCT01203007   Norway;Sweden
Tarpeyo 4 MG delayed release oral capsule
   Ruijin Hospital
      2023   -   NCT06589752   China
Telitacicept
   Ningxia Medical University General
      2024   Phase 0   ChiCTR2400083794   China
   RemeGen Co., Ltd.
      2023   Phase 3   NCT05799287   China
   Second Affiliated Hospital, School of Medicine, Zhejiang University
      2023   Phase 2/Phase 3   NCT05596708   China
   Shandong Provincial Hospital
      2022   Phase 4   ChiCTR2200064790   China
   The First Affiliated Hospital of Nanchang University
      2024   Phase 4   ChiCTR2400092894   China
   The Second Hospital of Shanxi Medical University
      2024   -   ChiCTR2400083991   China
   Xijing hospital
      2023   Phase 4   ChiCTR2300076949   China
Telitacicept 160MG
   RemeGen Co., Ltd.
      2021   Phase 2   NCT04905212   United States
   West China Hospital of Sichuan University
      2025   -   ChiCTR2500096335   China
Telitacicept 240MG
   Affiliated Hospital of North Sichuan Medical College
      2024   Phase 0   ChiCTR2500098584   China
   RemeGen Co., Ltd.
      2021   Phase 2   NCT04905212   United States
   Ruijin Hospital
      2024   -   NCT06654596   China
Telmisartan
   Chinese General Hospital of PLA
      2010   -   ChiCTR-TRC-10000776   China
   Xiyuan Hospital, China Academy of Chinese Medical Sciences
      2021   -   ChiCTR2100049833   China
      2020   -   ChiCTR2000040161   China
      2019   -   ChiCTR1900022100   China
Tetracycline
   Tianjin Hospital
      2023   -   ChiCTR2500101762   China
THE YI-QI-QING-JIE herbal compound
   Guang'anmen Hospital of China Academy of Chinese Medical Sciences
      2019   Phase 2/Phase 3   NCT03418779   China
Tofacitinib
   Peking Union Medical College Hospital
      2022   -   ChiCTR2200066045   China
Tripterygium
   Hangzhou Hospital of Traditional Chinese Medicine
      2012   -   ChiCTR-TRC-12002228   China
   Nanjing University School of Medicine
      2009   -   NCT00885547   China
   Second Xiangya Hospital of Central South University
      2014   Phase 3   NCT02187900   China
Ultomiris
   ALEXION PHARMACEUTICALS INCORPORATED
      2021   Phase 2   EUCTR2020-001537-13-IT   Australia;Belgium;Canada;France;Germany;Italy;Korea, Democratic People's Republic of;Netherlands;Poland;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States
Ultomiris 300 MG/30 ML
   Dr. Alfons Segarra Medrano
      2022   Phase 4   EUCTR2021-005609-28-ES   Spain
Vaccino contro IL memingococco DI gruppo B
   NOVARTIS PHARMA AG
      2022   Phase 3   EUCTR2020-002200-40-IT   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Viet Nam
      2021   Phase 3   EUCTR2020-001049-38-IT   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Vietnam
Vaccino haemophilus influenzae B coniugato CON tossoidetetanico
   NOVARTIS PHARMA AG
      2022   Phase 3   EUCTR2020-002200-40-IT   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Viet Nam
Vaccino pneumococcico
   NOVARTIS PHARMA AG
      2022   Phase 3   EUCTR2020-002200-40-IT   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Viet Nam
      2021   Phase 3   EUCTR2020-001049-38-IT   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Vietnam
Valsartan
   ARB therapeutic society of IgA nephropathy
      2003   Phase 4   JPRN-C000000380   Japan
   Chinese Cardiovascular Association-HX Fund
      2023   Phase 4   ChiCTR2300076082   China
   Columbia University
      2009   Phase 4   NCT01129557   United States
   Guangdong General Hospital
      2007   Phase 4   NCT00426348   China
   Peking Union Medical College Hospital
      2016   Phase 4   NCT02765594   China
   Shanghai Dong Fang Hospital
      2022   -   ChiCTR2200063885   China
   Shanghai East Hospital (East Hospital Affiliated to Tongji University)
      2022   -   ChiCTR2200062663   China
   Shuguang Hospital affliliated to Shanghai Univesrity of TCM
      2016   -   ChiCTR-IOR-16010174   China
VIS649
   Visterra, Inc.
      2020   Phase 2   EUCTR2019-002531-29-GB   Australia;Canada;Czech Republic;Hong Kong;India;Japan;Korea, Republic of;Malaysia;Philippines;Singapore;Spain;Taiwan;Thailand;United Kingdom;United States
      2018   Phase 1   NCT03719443   United States
VT-001
   Vera Therapeutics, Inc.
      2022   Phase 2   EUCTR2020-004892-41-PL   Australia;Belgium;Canada;Czech Republic;Czechia;Germany;Greece;India;Korea, Republic of;Malaysia;Poland;Turkey;United Kingdom;United States
      2021   Phase 2   EUCTR2020-004892-41-GR   Australia;Belgium;Canada;Czech Republic;Czechia;Germany;Greece;India;Korea, Republic of;Malaysia;Poland;Turkey;United Kingdom;United States
      2021   Phase 2   EUCTR2020-004892-41-DE   Australia;Belgium;Canada;Czech Republic;Czechia;Germany;Greece;India;Korea, Republic of;Malaysia;Poland;Turkey;United Kingdom;United States
      2021   Phase 2   EUCTR2020-004892-41-CZ   Australia;Belgium;Canada;Czech Republic;Czechia;Germany;Greece;India;Korea, Republic of;Malaysia;Poland;Turkey;United Kingdom;United States
      2021   Phase 2   EUCTR2020-004892-41-BE   Australia;Belgium;Canada;Czech Republic;Czechia;Germany;Greece;India;Korea, Republic of;Malaysia;Poland;Turkey;United Kingdom;United States
Warfarin
   The Japanese Pediatric IgA Nephropathy of Treatment Study Group
      2001   -   JPRN-C000000363   Japan
      1998   -   JPRN-C000000374   Japan
   The Japanese Pediatric IgA Nephropathy of Treatment Study Group
      1998   -   JPRN-C000000375   Japan
Water
   Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
      2023   Phase 2   ChiCTR2400094993   China
Zigakibart
   Novartis Pharmaceuticals
      2025   Phase 3   NCT06858319   -